MET and non-small cell lung carcinoma: The MET pathway is partially compensatory to EGFR signaling and MET amplification is a well-established mechanism of EGFR kinase inhibitor resistance, though whether it will be a major mechanism of resistance to inhibitors such as poziotinib and mobocertinib in EGFR exon 20 insertion NSCLC is not yet known [73,74].